Mr. Richard T. Schumacher, President and CEO of PBI, discussed: “PBI’s UST platform provides the potential to deliver a remarkable advancement in developing special, high quality nanoemulsions of oil in water. A large series of personal care and consumption items, consisting of nutraceuticals, cosmetics, pharmaceuticals, food & drinks, all deal with the perplexing obstacle of getting active oil-based nutrients or healing ingredients to end up being quickly absorbable and efficient in the water-based biology of our bodies. The opportunity to combine our strong engineering and biotech capabilities with 2 business that currently supply product development and brand management in varied customer product locations is very interesting and allows us to plainly move the identity and market focus of the combined companies from science platforms to the worth shipment of schedule and efficiency of active ingredients in end products.”
Dr. Bobby Ghalili, President of Cannaworx, Inc., broadened: “My co-founder in Cannaworx is Dr. Adrienne Denese, MD, Ph.D., the founder, innovator and representative behind over $500 M in Dr. Denese SkinScience product line sales for the past 17 years on QVC. These skin care and anti-aging items become part of our prepared rollup of companies under Availa Bio. In our rapidly expanding line of ingenious human, veterinary and agricultural products, several of which integrate phytocannabinoids from hemp oil, we are using our own oral and topical exclusive bioavailability and absorption shipment innovation. The UST platform will now enable us to provide high performance nanoemulsions, even more increasing both bioavailability and absorption rates. Our prepared rollout of Cannaworx items over the coming months consists of 2 trademarked oral phytocannabinoid formulas that integrate signs for discomfort relief allowed under an FDA OTC monograph. We believe our combined portfolios of copyright will offer Availa Bio a significant competitive advantage within the markets we serve.”
With an IP Estate of 31 issued and an extra dozen or more pending patents, an existing worldwide base of numerous corporate and countless retail clients, numerous items already on the market with many more anticipated to be launched in the weeks and months ahead, Availa Bio plans to disrupt large, addressable markets, as it marches toward profitability and increased shareholder value. The marketplaces expected to be served include: the U.S. hemp-derived CBD market (prepared for to reach $237 billion by 2023), the worldwide cosmetics market (predicted at $758 billion by 2025), the international biopharmaceuticals market (anticipated to reach $389 billion by 2024), the worldwide food & farming innovation and products market (approximated at $729 billion by 2023), and the worldwide food and drink market.
Dr. Denese, President of SkinScience Labs, added her interest for the combination of the 3 business: “My decades of development and marketing of skin care and anti-aging items that satisfy the scrutiny and demands of an exceptionally loyal following of customers has actually constantly needed us to be leaders in quality and performance, not simply for outcomes but in the whole item experience viewed by our users. We rapidly recognized that the Ultra Sheer Technology platform used the chance to improve not just the efficiency of our existing, highly-regarded formulas, however likewise to achieve new heights within the whole cosmetics market.”
The Letter of Intent in between Cannaworx, Inc. and SSL, and the Letter of Intent in between PBI and Cannaworx, Inc. are subject to particular closing conditions, including completion of all due diligence and acquisition funding.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly allowing, pressure-based options for the around the world life sciences and other markets. Our items are based upon the unique residential or commercial properties of both continuous (i.e., fixed) and alternating (i.e., pressure biking innovation, or PCT) hydrostatic pressure. PCT is a trademarked enabling innovation platform that utilizes rotating cycles of hydrostatic pressure in between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the advancement of PCT-based items for biomarker and target discovery, drug design and advancement, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, significant brand-new market opportunities have emerged in making use of our pressure-based innovations in the following areas: (1) making use of our recently obtained, trademarked innovation from BaroFold, Inc. (the “BaroFold” technology) to permit entry into the bio-pharma contract services sector, and (2) making use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (” UST”) platform to (i) develop stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare greater quality, homogenized, extended shelf-life or space temperature stable low-acid liquid foods that can not be successfully preserved using existing non-thermal innovations.
Forward Looking Statements
This press release contains positive declarations. These dangers, unpredictabilities, and other aspects include, but are not restricted to, the threats and unpredictabilities talked about under the heading “Danger Elements” in the Company’s Yearly Report on Kind 10- K for the year ended December 31, 2019, and other reports submitted by the Company from time to time with the SEC.
For additional information about PBI and this news release, please click the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President & CEO (508) 230-1828(T)
Jeffrey N. Peterson, Chairman (650) 703-8557(T)
SOURCE Pressure BioSciences, Inc.